Iron Treatment Strategies in Dialysis-Dependent CKD

Seminars in Nephrology

Volumn 36, Issue 2, 2016, Pages 105-111

  Pandey, Richa ^a   Daloul, Reem ^a   Coyne, Daniel W ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEPCIDIN; MYOGLOBIN; PROTOPORPHYRIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; ANTIANEMIC AGENT; DISACCHARIDE; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC ION; FERRITIN; HEMOGLOBIN; IRON DERIVATIVE; IRON DEXTRAN; IRON ISOMALTOSIDE 1000; IRON SACCHARATE; MAGNETITE; MALTOSE; SACCHARIC ACID;

CHRONIC KIDNEY DISEASE; ENERGY METABOLISM; ERYTHROID CELL; ERYTHROPOIESIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPOXIA; IRON ABSORPTION; IRON BALANCE; IRON BINDING CAPACITY; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON OVERLOAD; IRON RESTRICTION; IRON TRANSPORT; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; STEADY STATE; ANALOGS AND DERIVATIVES; CHRONIC KIDNEY FAILURE; COMPLICATION; HEMODIALYSIS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; DISACCHARIDES; FERRIC COMPOUNDS; FERRITINS; FERROSOFERRIC OXIDE; GLUCARIC ACID; HEMATINICS; HEMOGLOBINS; HUMANS; IRON COMPOUNDS; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; MALTOSE; RENAL DIALYSIS; TRANSFERRIN;

EID: 84969567616     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2016.02.004     Document Type: Review

References (53)

1. Eschbach J.W., Cook J.D., Scribner B.H., Finch C.A. Iron balance in hemodialysis patients. Ann Intern Med 1977, 87:710-713.
2. Longnecker R.E., Goffinet J.A., Hendler E.D. Blood loss during maintenance hemodialysis. Trans Am Soc Artif Intern Organs 1974, 20A:135-140.
3. Conrad M.E. Regulation of iron absorption. Prog Clin Biol Res 1993, 380:203-219.
4. Markowitz G.S., Kahn G.A., Feingold R.E., Coco M., Lynn R.I. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997, 48:34-40.
5. Fudin R., Jaichenko J., Shostak A., Bennett M., Gotloib L. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998, 79:299-305.
6. Macdougall I.C., Tucker B., Thomson J., et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996, 50:1694-1699.
7. Wingard R.L., Parker R.A., Ismail N., Hakim R.M. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995, 25:433-439.
8. Nissenson A.R., Berns J.S., Sakiewicz P., et al. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis 2003, 42:325-330.
9. Hallberg L., Hultén L., Gramatkovski E. Iron absorption from the whole diet in men: how effective is the regulation of iron absorption?. Am J Clin Nutr 1997, 66:347-356.
10. Barraclough K.A., Brown F., Hawley C.M., Leary D., Noble E., Campbell S.B., et al. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrol Dial Transplant 2012, 27:4146-4153.
11. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. PubMed - NCBI. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/?term=18845368.
12. Albaramki J., Hodson E.M., Craig J.C., Webster A.C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012, 1:CD007857.
13. Auerbach M., Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010, 2010:338-347.
14. Danielson B.G. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004, 15(Suppl 2):S93-S98.
15. Fishbane S., Ungureanu V.D., Maesaka J.K., et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996, 28:529-534.
16. Chertow G.M., Mason P.D., Vaage-Nilsen O., Ahlmén J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004, 19:1571-1575.
17. Wang C., Graham D.J., Kane R.C., Xie D., Wernecke M., Levenson M., et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015, 314:2062-2068.
18. Michael B., Coyne D.W., Fishbane S., et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002, 61:1830-1839.
19. Aronoff G.R., et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004, 66:1193-1198.
20. Folkert V.W., Michael B., Agarwal R., et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration. Am J Kidney Dis 2003, 41:651-657.
21. Onken J.E., Bregman D.B., Harrington R.A., et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant 2014, 29:833-842.
22. Onken J.E., Bregman D.B., Harrington R.A., et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2014, 54:306-315.
23. Covic A., Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant 2010, 25:2722-2730.
24. Provenzano R., Schiller B., Rao M., et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009, 4:386-393.
25. Macdougall I.C., Strauss W.E., McLaughlin J., et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014, 9:705-712.
26. FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). Available from:. http://www.fda.gov/Drugs/DrugSafety/ucm440138.htm.
27. Kamanna V.S., Ganji S.H., Shelkovnikov S., Norris K., Vaziri N.D. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration. Am J Nephrol 2012, 35:114-119.
28. Scheiber-Mojdehkar B., Lutzky B., Schaufler R., Sturm B., Goldenberg H. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. J Am Soc Nephrol 2004, 15:1648-1655.
29. Besarab A., Kaiser J.W., Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999, 34:21-28.
30. Brookhart M.A., Freburger J.K., Ellis A.R., et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013, 24:1151-1158.
31. Bailie G.R., Larkina M., Goodkin D.A., Li Y., Pisoni R.L., Bieber B., et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015, 87:162-168.
32. Fishbane S., Kowalski E.A., Imbriano L.J., Maesaka J.K. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996, 7:2654-2657.
33. Lin J.L., Chang M.Y., Tan D.T., Leu M.L. Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients. Am J Nephrol 2001, 21:91-97.
34. Mittman N., Sreedhara R., Mushnick R., et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997, 30:912-922.
35. Mitsuiki K., Harada A., Miyata Y. Assessment of iron deficiency in chronic hemodialysis patients: investigation of cutoff values for reticulocyte hemoglobin content. Clin Exp Nephrol 2003, 7:52-57.
36. Gotloib L., Silverberg D., Fudin R., Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006, 19:161-167.
37. Stancu S., Bârsan L., Stanciu A., Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?. Clin J Am Soc Nephrol 2010, 5:409-416.
38. Worwood M. Ferritin. Blood Rev 1990, 4:259-269.
39. Rogers J.T., Bridges K.R., Durmowicz G.P., et al. Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 1990, 265:14572-14578.
40. Kwak E.L., Larochelle D.A., Beaumont C., Torti S.V., Torti F.M. Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem 1995, 270:15285-15293.
41. Kalantar-Zadeh K., Rodriguez R.A., Humphreys M.H. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004, 19:141-149.
42. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study. J Am Soc Nephrol 2007, 18:975-984.
43. Kapoian T., O'Mara N.B., Singh A.K., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008, 19:372-379.
44. Pizzi L.T., Bunz T.J., Coyne D.W., Goldfarb D.S., Singh A.K. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int 2008, 74:1588-1595.
45. Coyne D.W., Sims A., Bingel B. Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate. Nephrol Nurs J 2008, 35:583-587.
46. Milman N. Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. Clin Nephrol 1982, 17:77-81.
47. Dittrich E., et al. Is absorption of high-dose oral iron sufficient in peritoneal dialysis patients?. Perit Dial Int 2000, 20:667-673.
48. Domoto D.T., Martin K.J. Failure of CAPD patients to respond to an oral iron absorption test. Adv Perit Dial 1992, 8:102-104.
49. Tinawi M., Martin K.J., Bastani B. Oral iron absorption test in patients on CAPD: comparison of ferrous sulfate and a polysaccharide ferric complex. Nephron 1996, 74:291-294.
50. Li H, Wang S-X. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int. 1008;28:149-154.
51. Ficheux M., Cuny P., Lecouf A., et al. Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis. Nephrol Ther 2011, 7:558-561.
52. Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J Am Soc Nephrol 1998, 9:664-668.
53. Johnson D.W., Herzig K.A., Gissane R., et al. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients. Nephrol Dial Transplant 2001, 16:1879-1884.